Compare Johnson & Johnson (JNJ) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Redwire Corporation — how do they compare? Johnson & Johnson trades at $248.08 (market cap $598.96B), while Redwire Corporation trades at $8.91 (market cap $2.05B). The key difference: Johnson & Johnson is far larger — about 292.2× Redwire Corporation's market cap, and Johnson & Johnson pays a 2.15% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| JNJ | RDW | |
|---|---|---|
Market Cap | $598.96B | $2.05B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $25.90 |
52-Week Low | $164.36 | $5.06 |
Enterprise Value | $631.90B | $2.12B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
RDW trades at $8.60, down 1.78% on the day, with a bearish technical signal despite bullish oscillators. The company reported a net loss of $226.55 million in 2025, with negative margins and cash flow from operations. Recent news highlights a record $498 million backlog and contract wins, but concerns over dilution and losses persist. The stock is near its support levels with resistance at $9.
The outlook is mixed: strong analyst buy ratings and a $19 consensus price target suggest upside, but fundamental weaknesses and cash burn pose significant risks. Investment opportunity hinges on execution improving profitability, while key risks include continued losses and competitive pressures in the aerospace sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
